ClinicalTrials.gg

Program

salanersen

Also written as “Salanersen” and “BIIB115”.

Its studies are mostly in Muscular Atrophy, Spinal, led by Biogen.

Furthest: phase 3, since Oct 24, 20254 company-led studies, 4 open or runningNext primary completion: Jun 23, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Biogen44 open or runningphase 3since Oct 24, 2025Oct 7, 2022Jun 23, 2028phase 3 · NCT07444476

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 7, 2022First study: phase 1 study in Muscular Atrophy, SpinalFirst studyNCT05575011 · 62 enrolled · Belgium, Canada, France and more
  2. Oct 24, 2025Phase 3 study in Muscular Atrophy, SpinalNCT07221669 · 30 planned · United States, Australia, Brazil and more
  3. Feb 26, 20262 phase 3 studies in Muscular Atrophy, SpinalNCT07444476, NCT07444450

Ahead

  1. Jun 23, 2028Primary completion: phase 3 study in Muscular Atrophy, SpinalNCT07444476
  2. Nov 28, 2028Primary completion: phase 3 study in Muscular Atrophy, SpinalNCT07221669
  3. Jul 27, 2029Primary completion: phase 3 study in Muscular Atrophy, SpinalNCT07444450
  4. Nov 14, 2031Primary completion: phase 1 study in Muscular Atrophy, SpinalNCT05575011

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07444476Muscular Atrophy, Spinal · United States, China, Japan and more3RecruitingJun 23, 202890
NCT07444450Muscular Atrophy, Spinal · United States3RecruitingJul 27, 202942
NCT07221669Muscular Atrophy, Spinal · United States, Australia, Brazil and more3RecruitingNov 28, 202830
NCT05575011Muscular Atrophy, Spinal · Belgium, Canada, France and more1Active, not recruitingNov 14, 203162

How it is read

Names in the registry

  • “Salanersen”, 3 entries
  • “BIIB115”, 1 entry

Codes read as this program: BIIB115.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
salanersen (Biogen): development program | ClinicalTrials.gg